Mycobacteria other than tuberculosis – prevalence, symptoms, diagnostics and treatment

Marcin Kołodziej, Dominik Puls, Justyna Puls, Bartłomiej Pala, Łukasz Więcek, Piotr Promiński, Martyna Promińska


As a class of bacteria, mycobacteria other than tuberculosis (MOTT), also known as nontuberculosis mycobacteria (NTM), affect both immunocompetents and immunodeficients. Non-specific clinical symptoms caused by these bacteria include respiratory diseases, which often results in delayed diagnosis. This article discusses the spread, diagnosis, symptoms, and treatment of MOTT in the world. In view of the fact that NTM are prevalent in the environment, their isolation from the upper respiratory system of the respiratory tract does not necessarily indicate an active infection. To make an accurate diagnosis, clinical, radiographic, and microbiological factors must be considered. Clinical symptoms of NTM infection can be difficult to diagnose, even for experienced clinicians, due to their similarity to Mycobacterium tuberculosis infection. Based on the determined antibiogram, targeted treatment can be selected based on identification and drug susceptibility of the microorganism. There are a variety of therapeutic options, depending on the pathogen’s growth rate. However, it is always important to keep in mind the side effects of the drugs used and to choose the best treatment based on the individual patient’s clinical condition.


mycobacteria other than tuberculosis; tuberculosis pneumonia; nontuberculosis mycobacteria; tuberculosis treatment

Full Text:



Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med 2015;36(1):35-41.

Honda JR, Virdi R, Chan ED. Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches. Front Microbiol 2018;9:2029.

Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res 2020;152(3):185-226.

Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis 2019;13(2):e0007083.

Hoefsloot W, van Ingen J, Andrejak C, Ängeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013;42(6):1604-13.

van der Werf MJ, Ködmön C, Katalinić-Janković V, Kummik T, Soini H, Richter E, et al. Inventory study of non-tuberculous mycobacteria in the European Union. BMC Infect Dis 2014;14:62.

Schildkraut JA, Gallagher J, Morimoto K, Lange C, Haworth C, Floto RA, et al. Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respir Med 2020;173:106164.

Kwiatkowska S, Augustynowicz-Kopeć E, Korzeniewska-Koseła M, Filipczak D, Gruszczyński P, Zabost A, et al. Nontuberculous mycobacteria strains isolated from patients between 2013 and 2017 in Poland. Our data with respect to the global trends. Adv Respir Med 2018;86(6):291-8.

Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010. Emerg Infect Dis 2013;19(11):1889-91.

Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185(8):881-6. doi: 10.1164/rccm.201111-2016OC.

Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007–2012. BMC Infect Dis 2016;16:195.

Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PNR, Boeree MJ, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011;17(3):343-9.

Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 2014;11(1):1-8.

Jing H, Wang H, Wang Y, Deng Y, Li X, Liu Z, et al. Prevalence of nontuberculous mycobacteria infection, China, 2004–2009. Emerg Infect Dis 2012;18(3):527-8.

Chou MP, Clements AC, Thomson RM. A spatial epidemiological analysis of nontuberculous mycobacterial infections in Queensland, Australia. BMC Infect Dis 2014;14:279.

Koh WJ, Chang B, Jeong BH, Jeon K, Kim SY, Lee NY, et al. Increasing Recovery of nontuberculous mycobacte-ria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea. Tuberc Respir Dis (Seoul) 2013;75(5):199-204.

Koh WJ. Nontuberculous mycobacteria – overview. Microbiol Spectr 2017;5(1). doi: 10.1128/microbiolspec.

Gopalaswamy R, Shanmugam S, Mondal R, Subbian S. Of tuberculosis and non-tuberculous mycobacterial infections – a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci 2020;27(1):74.

Pennington KM, Vu A, Challener D, Rivera CG, Shweta FNU, Zeuli JD, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis 2021;24:100244.

Raju RM, Raju SM, Zhao Y, Rubin EJ. Leveraging advances in tuberculosis diagnosis and treatment to address nontuberculous mycobacterial disease. Emerg Infect Dis 2016;22(3):365-9.

Katoch VM. Infections due to non-tuberculous mycobacteria (NTM). Indian J Med Res 2004;120(4):290-304.

Meoli A, Deolmi M, Iannarella R, Esposito S. Non-tuberculous mycobacterial diseases in children. Pathogens 2020;9(7):553.

Rapp RP, McCraney SA, Goodman NL, Shaddick DJ. New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis. Ann Pharmacother 1994;28(11):1255-63. doi: 101177/106002809402801109.


Copyright (c) 2023 Marcin Kołodziej

License URL: